AffyImmune Therapeutics is a clinical-stage biotechnology company founded in 2016 that optimizes CAR T cells for the treatment of solid tumors. The company is based on technology licensed from Weill Cornell Medical Center relating to the affinity tuning of CAR T cells. In addition, the CAR T cells we are using are engineered to express a receptor that allows for imaging of the cells in patients in real time. The company is currently enrolling patients with advanced, refractory thyroid cancer in a trial of our lead compound, which is specifically directed to kill tumor cells overexpressing ICAM-1 while sparing normal cells expressing basal levels.
AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy.